The results of the sequential use of Mexidol and Mexidol Forte 250 in patients with chronic brain ischemia

Author:
Yu. V. ABRAMENKO

FSBEI in the Tver State Medical University of the Ministry of Health of Russia, Tver, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY 2020, Vol. 120, No. 3, Issue 2, pp. 60-65

Abstract:
Objective of the study. To study the efficacy and safety of Mexidol therapy administered intravenously by jet stream (500 mg once a day) for 14 days, followed by oral administration of Mexidol FORTE 250 at a dose of 250 mg (1 tablet) 3 times a day for 60 days in patients with chronic cerebral ischemia (CCI) associated with arterial hypertension and atherosclerosis of the brachiocephalic arteries. Material and methods. The observation program included 52 patients with an established diagnosis of CCI, confirmed by neuroimaging methods. The main group included 26 patients who received, in addition to basic therapy, Mexidol and Mexidol Forte 250. The comparison group consisted of 26 patients who received only basic therapy. Results and conclusion. High efficacy and safety of sequential therapy (parenteral administration followed by oral administration of Mexidol FORTE 250) have been demonstrated. Improvements in emotional and cognitive status, a reduction in static-locomotor disturbances, and the severity of subjective neurological symptoms were noted during treatment. High patient compliance was demonstrated. Key words: chronic cerebral ischemia, arterial hypertension, brachiocephalic artery atherosclerosis, Mexidol, static-locomotor disturbances, cognitive impairment.